Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Viridian Therapeutics, Inc. or Immunocore Holdings plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Viridian Therapeutics, Inc. and Immunocore Holdings plc compare based on key financial metrics to determine which better meets your investment needs.

About Viridian Therapeutics, Inc. and Immunocore Holdings plc

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Latest Biotechnology and Viridian Therapeutics, Inc., Immunocore Holdings plc Stock News

As of November 26, 2025, Viridian Therapeutics, Inc. had a $3.0 billion market capitalization, compared to the Biotechnology median of $220.1 million. Viridian Therapeutics, Inc.’s stock is up 65.5% in 2025, up 10.6% in the previous five trading days and up 57.03% in the past year.

Currently, Viridian Therapeutics, Inc. does not have a price-earnings ratio. Viridian Therapeutics, Inc.’s trailing 12-month revenue is $70.8 million with a -426.6% net profit margin. As of November 26, 2025, Viridian Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-3.532 per share for the current fiscal year. Viridian Therapeutics, Inc. does not currently pay a dividend.

As of November 26, 2025, Immunocore Holdings plc had a $2.0 billion market cap, putting it in the 56th percentile of all stocks. Immunocore Holdings plc’s stock is up 36% in 2025, up 3.8% in the previous five trading days and up 24.32% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $379.6 million with a -7.7% net profit margin. Year-over-year quarterly sales growth most recently was 29.3%. There are no analysts providing consensus earnings estimates for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

How We Compare Viridian Therapeutics, Inc. and Immunocore Holdings plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Viridian Therapeutics, Inc. and Immunocore Holdings plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Viridian Therapeutics, Inc. and Immunocore Holdings plc Growth Grades

Company	Ticker	Growth
Viridian Therapeutics, Inc.	VRDN	F
Immunocore Holdings plc	IMCR	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Viridian Therapeutics, Inc. has a Growth Score of 1, which is Very Weak. Immunocore Holdings plc has a Growth Score of 27, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Viridian Therapeutics, Inc. or Immunocore Holdings plc has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Viridian Therapeutics, Inc. or Immunocore Holdings plc is the better investment when it comes to sustainable growth.

Viridian Therapeutics, Inc. and Immunocore Holdings plc’s Quality Grades

Company	Ticker	Quality
Viridian Therapeutics, Inc.	VRDN	F
Immunocore Holdings plc	IMCR	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Viridian Therapeutics, Inc. has a Quality Score of 5, which is Very Weak. Immunocore Holdings plc has a Quality Score of 59, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Viridian Therapeutics, Inc. or Immunocore Holdings plc has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Viridian Therapeutics, Inc. or Immunocore Holdings plc is the better investment when it comes to quality.

Viridian Therapeutics, Inc. and Immunocore Holdings plc’s Momentum Grades

Company	Ticker	Momentum
Viridian Therapeutics, Inc.	VRDN	A
Immunocore Holdings plc	IMCR	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Viridian Therapeutics, Inc. has a Momentum Score of 92, which is Very Strong. Immunocore Holdings plc has a Momentum Score of 77, which is Strong.

The Momentum Grade Winner: Viridian Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Viridian Therapeutics, Inc. is considered to have stronger momentum compared to Immunocore Holdings plc. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Viridian Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Viridian Therapeutics, Inc. and Immunocore Holdings plc Grades

In addition to Momentum, Quality and Growth, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Viridian Therapeutics, Inc. and Immunocore Holdings plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Viridian Therapeutics, Inc. or Immunocore Holdings plc Stock?

Overall, Viridian Therapeutics, Inc. stock has a Growth Score of 1, Momentum Score of 92 and Quality Score of 5.

Immunocore Holdings plc stock has a Growth Score of 27, Momentum Score of 77 and Quality Score of 59.

Comparing Viridian Therapeutics, Inc. and Immunocore Holdings plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.